Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
CombinatoRx, Incorporated
CombinatoRx Collaborator Fovea Reports Encouraging Clinical Results with CombinatoRx-Derived Combination Drug Candidate
May 23rd, 2009
CombinatoRx, Incorporated (Nasdaq Global Market: CRXX) announced that its ophthalmics collaborator, Fovea Pharmaceuticals, reported positive results from its clinical proof-of-concept trial to assess the therapeutic effect of a CombinatoRx-derived combination drug candidate, PrednisporinTM (FOV1101), in subjects with persistent allergic conjunctivitis. Based on these data, Fovea has announced its intentions to prepare further advanced trials for PrednisporinTM both in the USA and in Europe. “We are pleased to see the successful translation of the CombinatoRx drug discovery approach from screening into human clinical development into a new indication on behalf of our...
Source: Law & Health Weekly (2009-05-23)
|
